Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03389893
Recruitment Status : Recruiting
First Posted : January 4, 2018
Last Update Posted : June 12, 2019
Sponsor:
Collaborators:
Regeneron Pharmaceuticals
Sanofi
Atopic Dermatitis Research Network
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019